Practice Test GeeksBCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test
← All BCACP Flashcard Decks

Cardiovascular Risk Reduction Flashcards

7 cards from real BCACP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Cardiovascular Risk Reduction flashcards as text

  1. A 72-year-old woman with hypertension, osteoporosis, and no prior CV events has a 10-year ASCVD risk of 9%. The clinician and patient are uncertain about statin therapy. What is the most appropriate next step?

    Answer: Use risk-enhancing factors to guide the statin discussion

    For borderline-risk patients (7.5–20%), ACC/AHA guidelines recommend using risk-enhancing factors to refine the statin initiation decision.

  2. Which antihypertensive combination is generally AVOIDED due to risk of hyperkalemia, acute kidney injury, and hypotension?

    Answer: ACE inhibitor + ARB

    Dual RAAS blockade combining an ACE inhibitor with an ARB increases risk of hyperkalemia, AKI, and hypotension without additional CV benefit.

  3. A patient with atrial fibrillation and a CHA₂DS₂-VASc score of 3 is started on anticoagulation. Which factor is NOT included in the CHA₂DS₂-VASc score?

    Answer: Smoking history

    Smoking history is not a component of the CHA₂DS₂-VASc score; the score includes CHF, HTN, age, diabetes, stroke/TIA, vascular disease, and sex.

  4. A patient with hypertriglyceridemia (TG = 680 mg/dL) is at high risk for pancreatitis. Which is the most effective pharmacologic treatment?

    Answer: Fibrates

    Fibrates are the most effective agents for reducing very high triglycerides and are first-line to prevent pancreatitis in severe hypertriglyceridemia.

  5. Which of the following is a contraindication to initiating ACE inhibitor therapy?

    Answer: Bilateral renal artery stenosis

    Bilateral renal artery stenosis is a contraindication to ACE inhibitors because they can precipitate acute renal failure in this setting.

  6. The FOURIER trial demonstrated cardiovascular benefit for which medication class in patients with established ASCVD on statin therapy?

    Answer: PCSK9 inhibitors

    FOURIER showed that evolocumab (a PCSK9 inhibitor) significantly reduced major CV events in patients with ASCVD already on statin therapy.

  7. A 48-year-old with metabolic syndrome, LDL-C 135 mg/dL, and no clinical ASCVD has a coronary artery calcium (CAC) score of 0. What is the most appropriate recommendation?

    Answer: Defer statin therapy and reassess in 5–10 years

    A CAC score of 0 in a patient without clinical ASCVD indicates very low near-term CV risk and supports deferring statin therapy with reassessment.